Ibalizumab

DRUG5 trials

Sponsors

TaiMed Biologics Inc., University of Colorado, Denver, Epividian

Conditions

HIVHIV-1-infectionHuman Immunodeficiency Virus (HIV)

Phase 2

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

CompletedNCT00784147

TaiMed Biologics Inc.HIV

Start: 2008-08-31End: 2011-04-30Updated: 2014-05-05

Phase 3

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

CompletedNCT02475629

TaiMed Biologics Inc.HIV

Start: 2015-08-31End: 2016-12-31Updated: 2020-03-19

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

CompletedNCT02707861

TaiMed Biologics Inc.HIV

Start: 2016-03-31End: 2018-11-30Updated: 2021-03-11

Unknown Phase

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

University of Colorado, DenverHuman Immunodeficiency Virus (HIV)

Start: 2012-01-31End: 2014-02-28Updated: 2016-11-01

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

CompletedNCT05495204

EpividianHIV-1-infection

Start: 2022-08-05End: 2023-02-20Updated: 2023-09-07

Related Papers

Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced People Living With Multidrug-Resistant HIV-1: A Phase 3, Multicenter, Expanded Access Study

JAIDS Journal of Acquired Immune Deficiency Syndromes2025-06-04

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

New England Journal of Medicine2018-08-15220 citations